4th Circ. Revives Purdue Pharma OxyContin FCA Row

Law360, New York (December 12, 2013, 3:04 PM EST) -- The Fourth Circuit on Thursday revived a qui tam lawsuit accusing Purdue Pharma LP of violating the False Claims Act by falsely marketing painkiller OxyContin, vacating a lower court’s ruling that had tossed the case for being virtually identical to a previous one that was dismissed after being brought by the relator’s husband.

A three-judge panel found that the res judicata doctrine — which bars the filing of new cases that are nearly identical to cases that have already been litigated to conclusion — does not...
To view the full article, register now.